The FDA is yet to make a decision on the applications. Concerns over semaglutide Over the past year, Novo Nordisk has filed at least 50 lawsuits against clinics and pharmacies that have produced ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

The effects last only for a few hours. Examples include exenatide and lixisenatide. Ozempic: Novo Nordisk’s name-brand ...

Novo Nordisk A/S (NVO)'s share was trading at $109.09 as of Nov ... Driving NVO’s wide moat is a robust innovation pipeline ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk is working on a new obesity drug that could help ... could reignite Novo shares. Semaglutide, the GLP-1 drug ...